LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Accueil・Liste d'Actions・Xencor Inc

Xencor Inc

Fermé

SecteurSoins de santé

12.73 -1.09

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.7

Max

13.46

Chiffres clés
By Trading Economics
Revenu	92M 85M
Ventes	7.2M 28M
BPA	-0.09
Marge bénéficiaire	302.738
Employés	260
EBITDA	1.4M 5.7M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+102.18% upside

Dividendes
By Dow Jones
Prochains Résultats	12 mai 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	164M 990M
Ouverture précédente	13.82
Clôture précédente	12.73

Sentiment de l'Actualité

By Acuity

50%

175 / 346 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

7.87 / 10.84 Support & Résistance

Xencor Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 mai 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mai 2026, 23:46 UTC

Market Talk

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mai 2026, 23:33 UTC

Market Talk

Gold Rises on Possible Position Adjustments -- Market Talk

11 mai 2026, 22:37 UTC

Market Talk

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mai 2026, 22:32 UTC

Résultats

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mai 2026, 22:02 UTC

Market Talk

Principaux Événements d'Actualité

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mai 2026, 21:49 UTC

Résultats

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mai 2026, 21:42 UTC

Market Talk

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mai 2026, 21:32 UTC

Acquisitions, Fusions, Rachats

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mai 2026, 21:31 UTC

Acquisitions, Fusions, Rachats

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mai 2026, 21:23 UTC

Acquisitions, Fusions, Rachats

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mai 2026, 21:12 UTC

Résultats

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mai 2026, 21:12 UTC

Résultats

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

11 mai 2026, 20:44 UTC

Résultats

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mai 2026, 20:43 UTC

Résultats

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mai 2026, 20:32 UTC

Résultats

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mai 2026, 20:32 UTC

Résultats

CleanSpark 2Q Rev $136.4M >CLSK

11 mai 2026, 20:30 UTC

Résultats

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Cont Ops EPS $2.24 >STE

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Rev $1.6B >STE

11 mai 2026, 20:30 UTC

Résultats

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mai 2026, 20:30 UTC

Résultats

Steris 4Q Adj EPS $2.83 >STE

11 mai 2026, 20:22 UTC

Actions en Tendance

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mai 2026, 19:37 UTC

Résultats

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mai 2026, 19:32 UTC

Market Talk

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Comparaison

Variation de prix

Xencor Inc prévision

Objectif de Prix

By TipRanks

102.18% hausse

Prévisions sur 12 Mois

Moyen 26 USD 102.18%

Haut 43 USD

Bas 13 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

7.87 / 10.84Support & Résistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

175 / 346Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.